Analyst Rating Update on Akorn (AKRX)

Akorn (NASDAQ:AKRX) has an average broker rating of 1.67, which is interpreted as a Buy, as rated by 12 equity analysts. Nonetheless, 7 analysts are positive on the stocks future and they recommend a Strong Buy on the stock. 2 other analysts advise a Buy. Nevertheless, the majority of 3 analysts consider that the stock is a Hold with neither a large upside nor a downside. Ranking by Zacks Investment Research for Coach Inc is 3, which is also a Hold.

Akorn (NASDAQ:AKRX) : Currently there are 10 street experts covering Akorn (NASDAQ:AKRX) stock. The most bullish and bearish price target for the stock is $45 and $30 respectively for the short term. The average price target of all the analysts comes to $36.4. The estimated standard deviation from the target is $4.95.

For the current week, the company shares have a recommendation consensus of Buy.

Akorn (NASDAQ:AKRX): stock turned positive on Tuesday. Though the stock opened at $26.61, the bulls momentum made the stock top out at $28.15 level for the day. The stock recorded a low of $26.61 and closed the trading day at $28.02, in the green by 6.26%. The total traded volume for the day was 1,319,938. The stock had closed at $26.37 in the previous days trading.

In an insider trading activity, Bonaccorsi Joseph, officer (Sr VP Gen Counsel & Secretary) of Akorn Inc, unloaded 6,500 shares at an average price of $29.84 on June 14, 2016. The total amount of the transaction was worth $193,960, according to the disclosed information with the Securities and Exchange Commission in a Form 4 filing.

Akorn Inc. (Akorn), together with its wholly owned subsidiaries, is a specialty pharmaceutical company that develops, manufactures and markets generic and branded prescription pharmaceuticals, as well as animal and over-the-counter (OTC) consumer health products. The Company specializes in sterile and non-sterile dosage forms, including ophthalmics, injectables, oral liquids, otics, topicals, inhalants and nasal sprays. The Company operates in two segments: Prescription Pharmaceuticals, which is engaged in the sale of branded and generic prescription pharmaceuticals, and Consumer Health, which is engaged in the sale of branded and private label consumer and animal health products. The Company operates pharmaceutical manufacturing facilities in Decatur, Illinois; Somerset, New Jersey; Amityville, New York, and Paonta Sahib, Himachal Pradesh, India, as well as a central distribution warehouse in Gurnee, Illinois, and an additional warehousing facility in Amityville, New York.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *